ArticleVox sanguinis2026
Liquid plasma versus thawed plasma: Tracking coagulation factor activity changes during storage.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivesLiquid plasma (LQP) stands out as an alternative to thawed plasma (TP) for emergent transfusions due to its longer shelf-life. We aimed to measure fibrinogen, protein C (PC), protein S (PS), factor V (FV), factor VII (FVII) and factor VIII (FVIII) activity in LQP, quantify how these factors' levels change during storage and characterize how they compare in LQP and TP. MATERIALS AND
methodsCoagulation factor activities were measured on days 15, 26 and 27 for LQP (n = 26) and Day 5 for TP (n = 31). Bayesian statistics was used to compare coagulation factor activity and quantify changes in activity during storage.
resultsFibrinogen and PC activity on Day 26 in LQP (LQP26) was comparable to that on Day 5 in TP (TP5) with posterior mean activity of 257 versus 246 mg/dL and 100.4% versus 108.7%, respectively. FV, FVII and FVIII had lower activity in LQP26 compared to TP5, with posterior mean activities of 42.6% versus 72.0%, 55.0% versus 59.7% and 48.8% versus 59.2%, respectively. PS in LQP26 was low, with posterior mean activity of 28.0%, which was less than half that of TP5 at 66.4%. From Day 15 to Day 26, FVII in LQP decreased at a rate of 3.49% per day, whereas fibrinogen, PC, PS, FV and FVIII activity in LQP remained relatively stable.
conclusionLQP26 has comparable activities of fibrinogen, PC and FVII as TP5, lower activities of FV and PS and slightly lower activity of FVIII. LQP is a viable alternative for use in emergency transfusions and massive transfusion protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.